Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.

摘要: The Ki-67 antigen is used to evaluate the proliferative activity of breast cancer (BC); however, Ki-67's role as a prognostic marker in BC still undefined. In order better define value Ki-67/MIB-1, we performed meta-analysis studies that evaluated impact Ki-67/MIB-1 on disease-free survival (DFS) and/or overall (OS) early BC. Sixty-eight were identified and 46 including 12 155 patients evaluable for our meta-analysis; 38 aggregation results DFS, 35 OS. Patients considered present positive tumours expression according cut-off points defined by authors. positivity associated with higher probability relapse all (HR=1.93 (95% confidence interval (CI): 1.74-2.14); P<0.001), node-negative (HR=2.31 CI: 1.83-2.92); P<0.001) node-positive (HR=1.59 1.35-1.87); P<0.001). Furthermore, worse (HR=1.95 1.70-2.24; P<0.001)), (HR=2.54 1.65-3.91); (HR=2.33 1.83-2.95); Our suggests confers risk